Latest News
Conference Coverage
HDAC inhibition may boost immune therapy efficacy in breast cancer
ORLANDO – Entinostat and nivolumab with or without ipilimumab showed encouraging activity in early results from a phase 1 trial of patients with...
Conference Coverage
VIDEO: How to prepare PTCL patients for transplant
LA JOLLA, CALIF. – Dr. Steven Horwitz says the key to preparing patients for transplant is “good remission.”
From the Journals
MRI matches standard biopsy at detecting significant prostate cancers
Multiparametric MRI, with or without targeted biopsy, detected a higher proportion of clinically significant cancers than ultrasound-guided biopsy...
Daily News Podcast
MDedge Daily News: Is kratom the answer to the opioid crisis?
And specialists have adverse reactions to drug price proposals.
Conference Coverage
CBC data can predict immunotherapy responses in NSCLC
ORLANDO – Readily available complete blood count data can help predict response to immunotherapy in patients with advanced NSCLC.
Conference Coverage
VIDEO: Everolimus/letrozole promising for recurrent endometrial cancer
NEW ORLEANS – Phase 2 results show unexpectedly high efficacy for everolimus/letrozole in chemotherapy-naive...
From the Journals
Lower socioeconomic status linked with poor NSCLC prognosis in those with pretreatment weight loss
Socioeconomic status, as measured by insurance status, was significantly prognostic among patients with NSCLC and pretreatment weight loss, but...
From the Journals
Late toxicities with PARP inhibitor plus RT in inflammatory breast cancer
Using a PARP inhibitor as a radiosensitizer in treatment of women with inflammatory breast cancer was associated with late grade 3 adverse events...
News
FDA approves nilotinib for children with CML
The decision expands the drug’s indication to include first- and second-line use in children.
Daily News Podcast
MDedge Daily News: Treating H. pylori slashed new gastric cancers
And the Supreme Court considers California’s abortion speech law.
From the Journals
Experimental voxtalisib shows mixed results in phase 2 study
The novel pan-P13K/mTOR inhibitor induced complete responses in some patients with follicular lymphoma, but not aggressive malignancies, including...